If the ongoing trial results demonstrate that aspirin beneficially alters skin or blood biomarkers—for example, by reducing inflammatory mediators or increasing tissue AMPK activation—this could pave the way for larger studies investigating whether aspirin can reduce melanoma incidence or improve patient outcomes. This evidence concerns the gene PRKAB1 and melanoma.